bs-0982R **[Primary Antibody]**

RELA | NFκB p65 (p-S536) Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 5970 **SWISS:** Q04206

Target: RELA | NFκB p65 (p-S536)

Immunogen: KLH conjugated Synthesised phosphopeptide derived from human NFKBp65 around the phosphorylation site of Ser536: FS(p-S)IA.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: NF-kappa-B is a ubiquitous transcription factor involved in several biological processes. It is held in the cytoplasm in an inactive state by specific inhibitors. Upon degradation of the inhibitor, NF-kappa-B moves to the nucleus and activates transcription of specific genes. NF-kappa-B is composed of NFKB1 or NFKB2 bound to either REL, RELA, or RELB. The most abundant form of NF-kappa-B is NFKB1 complexed with the product of this gene, RELA. Four transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2011].

Applications: **WB** (1:500-2000)

Reactivity: Mouse (predicted: Human, Rat, Monkey)

Predicted MW.: 61 kDa

Observed MW.: 65 kDa

Subcellular Location: Cytoplasm ,Nucleus

VALIDATION IMAGES



NIH/3T3 (M) cells were treated with or without Calyculin A (100nM) for 30 min, 25 µg total protein per lane of cell lysates (see on figure) probed with phospho-NFKB p65 polyclonal antibody, unconjugated (bs-0982R) at 1:2000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.

SELECTED CITATIONS

- **[IF=19]** Xuezhe Liu. et al. Transient Hyperoxia-Generating Interface Coupled with Mg2+ Delivery Reprograms Osteoimmune Microenvironment for Enhancing Osseointegration. ADV FUNCT MATER. 2025 Sep;:e14674 WB ;Mouse. 10.1002/adfm.202514674
- **[IF=17.521]** Yi Yan. et al. Nanomedicines Reprogram Synovial Macrophages by Scavenging Nitric Oxide and Silencing CA9 in Progressive Osteoarthritis. Advanced Science. 2023 Feb;:2207490 WB ;Mouse. 36748885
- **[IF=15.304]** Sitong Liu. et al. MRI-visible mesoporous polydopamine nanoparticles with enhanced antioxidant capacity for osteoarthritis therapy. BIOMATERIALS. 2023 Apr;295:122030 WB ;Mouse. 36758340
- **[IF=12.4]** Manikandan Santhanam. et al. Interaction of SMAC with a survivin-derived peptide alters essential cancer

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

hallmarks: Tumor growth, inflammation, and immunosuppression. MOL THER. 2024 Apr 05 WB ;Mouse. 38582961

- **[IF=11.7]** Ran Cheng. et al.Intratumoral antigen-presenting cell activation by a nanovesicle for the concurrent tertiary lymphoid structure de novo neogenesis.science advances.2025 Feb 21;11(8):eadr1299. ;Mouse. 39970209

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.